Request Demo
Last update 27 Feb 2026
OPS-2071
Last update 27 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms OPS 2071 |
Action inhibitors |
Mechanism Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC20H15FN4O3 |
InChIKeyDTSKYQBTFHFYAZ-UHFFFAOYSA-N |
CAS Registry1426216-93-4 |
Related
4
Clinical Trials associated with OPS-2071NCT05923892
A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Different Doses of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
NCT03850509
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Trial to Assess the Efficacy and Safety of Orally Administered OPS-2071 for 12 Weeks in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation Despite Ongoing Treatment
NCT02473393
A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis
100 Clinical Results associated with OPS-2071
Login to view more data
100 Translational Medicine associated with OPS-2071
Login to view more data
100 Patents (Medical) associated with OPS-2071
Login to view more data
6
Literatures (Medical) associated with OPS-207128 Nov 2022The Journal of antimicrobial chemotherapy
In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria
Article
Author: Suzuki, Yasuhiko ; Matsumoto, Makoto ; Yamaguchi, Tomoyuki ; Changkwanyeun, Ruchirada ; Oka, Daisuke ; Nakajima, Chie
Abstract:
Background:
Enteric infections are a major public health issue in developing countries. Antimicrobial resistance is also a problem for enteric infection. OPS-2071 is a novel quinolone antibiotic with low oral absorption and potent antibacterial activity against Clostridioides difficile.
Objectives:
This study was conducted to confirm the antimicrobial activity of OPS-2071 against major enteropathogenic bacteria and to evaluate the risk of emergence of drug resistance.
Methods:
The antibacterial activity was evaluated by the agar dilution method. The inhibitory activity against DNA gyrase and topoisomerase IV was determined by supercoiling assay and decatenation assay, respectively. The mutant prevention concentration and frequency of spontaneous resistance were determined by inoculation on drug-containing agar.
Results:
Compared with the reference drugs, the antibacterial activity of OPS-2071 was more potent against Gram-positive bacteria and Campylobacter jejuni, including quinolone-resistant strains. Against other Gram-negative bacteria, OPS-2071 was comparable to existing quinolones. The inhibitory activities against DNA gyrase with quinolone-resistant mutations closely correlated with the antibacterial activity. Spontaneous resistance to OPS-2071 was not observed in Staphylococcus aureus and Escherichia coli and was lower than that of existing quinolones and higher than that of azithromycin in C. jejuni. The mutant prevention concentration of OPS-2071 was lower than that of tested compounds in S. aureus and C. jejuni and slightly higher than that of existing quinolones in E. coli.
Conclusions:
The broad and potent in vitro antibacterial activity and lower risk of drug resistance suggested that OPS-2071 may be useful for enteric infections caused by major pathogens including quinolone-resistant Campylobacter.
01 Aug 2022Digestive diseases and sciencesQ3 · MEDICINE
Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease
Q3 · MEDICINE
Article
Author: Yamaya, Naomitsu ; Sato, Masayoshi ; Hagita, Hiraku ; Inagaki, Katsuya ; Shibuya, Isao ; Matsumoto, Makoto ; Takagi, Hiroko ; Fujii, Kazuyuki ; Oka, Daisuke
BACKGROUND:
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract. Although many types of drug are used, clinical outcomes are still unsatisfactory. Previous studies have suggested that intestinal bacteria are involved in the pathogenesis of IBD. Accordingly, in an IBD model we evaluated the therapeutic effects of OPS-2071, a low-absorption quinolone antibacterial agent indicated for intestinal infection, and investigated its mechanism of action.
METHODS:
The therapeutic effects of OPS-2071 and comparison therapies were evaluated using naive CD4 + T cell-transfer IBD model mice. In vitro inhibition of LPS-induced TNF-α production and inhibitory effects on T cell responses stimulated using anti-CD3/CD28 antibody-loaded beads were evaluated using mouse splenocytes and human peripheral blood mononuclear cells. In addition, in vitro activities against bacteria implicated in IBD pathogenesis were tested.
RESULTS:
OPS-2071 dose-dependently decreased both colonic weight/length ratio and the colitis histological score as compared with the vehicle group. The therapeutic effect of OPS-2071 was equivalent to that of anti-IL-12/23 (p40) antibody. In vitro, OPS-2071 suppressed TNF-α production induced by LPS stimulation and T cell responses in a dose-dependent manner. At high concentrations, these effects were comparable to those of existing immunosuppressive agents, such as prednisolone, in both mouse and human cells. OPS-2071 also showed antibacterial activity against IBD-related bacteria.
CONCLUSIONS:
Our results suggest that OPS-2071 had both immunosuppressive and antibacterial effects. This dual effect makes OPS-2071 a unique and promising candidate for IBD.
01 Jul 2022Digestive diseases and sciencesQ3 · MEDICINE
Novel Gut Microbiota Modulator, Which Markedly Increases Akkermansia muciniphila Occupancy, Ameliorates Experimental Colitis in Rats
Q3 · MEDICINE
Article
Author: Nakashima, Takako ; Seki, Toyokazu ; Kawasome, Hideki ; Fujii, Kazuyuki ; Aoyama, Masashi ; Azuma, Atsushi
BACKGROUND:
Since gut microbiota is involved in the pathogenesis of inflammatory bowel disease (IBD), antibiotics or probiotics may be attractive options for the treatment of IBD. Akkermansia muciniphila is expected as a next-generation probiotic for IBD, and OPS-2071 is a novel quinolone with potent antibacterial activity against Clostridioides difficile.
AIMS:
The aim of this study is to assess the potential of OPS-2071 as a gut microbiota modulator for IBD.
METHODS:
Minimum inhibitory concentrations of several bacteria in the human intestinal microbiota were determined. Microbiota changes in the feces were typed using metagenomic analysis after oral administration of OPS-2071 (100 mg/kg) twice a day to normal rats. The amounts of mucin were determined using the Fecal Mucin Assay Kit. The effects of OPS-2071 (1, 3, 10 mg/kg) twice a day on fecal symptoms and fecal microbiota were evaluated in a colitis rat model induced by free access to drinking water containing 3% dextran sulfate sodium for 10 days.
RESULTS:
OPS-2071 showed notably low antibacterial activity against only A. muciniphila in spite of higher antimicrobial activity against other strains of intestinal bacteria. OPS-2071 rapidly and dramatically increased the occupancy of A. muciniphila as well as the amount of mucin in the feces of normal rats. OPS-2071 (10 mg/kg) significantly suppressed the exacerbation of stool scores, especially the bloody stool score, with the increase in A. muciniphila occupancy.
CONCLUSIONS:
OPS-2071 is expected to be a new therapeutic option for IBD as a gut microbiota modulator by significantly increasing A. muciniphila occupancy.
100 Deals associated with OPS-2071
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Irritable bowel syndrome with diarrhea | Phase 2 | China | 27 Jun 2023 | |
| Crohn Disease | Phase 2 | Italy | 11 Feb 2020 | |
| Inflammation | Phase 2 | Italy | 11 Feb 2020 | |
| Bacterial enteritis | Phase 2 | Japan | 20 Aug 2015 | |
| Bacterial enteritis | Phase 2 | Singapore | 20 Aug 2015 | |
| Bacterial enteritis | Phase 2 | South Korea | 20 Aug 2015 | |
| Clostridium difficile infection | Preclinical | China | 18 Mar 2021 | |
| Clostridium difficile infection | Preclinical | Japan | 18 Mar 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 3 | (OPS-2071 300 mg BID) | hhqwekhohb = xwzkeugipc fynsdhmlsd (dkjojgzuen, xcfntwmudo - pcvwwttsjx) View more | - | 15 Jun 2021 | ||
Placebo (Placebo) | hhqwekhohb = qpntbtixzg fynsdhmlsd (dkjojgzuen, yvzkvotbgj - iljfaeceys) View more | ||||||
Phase 2 | 43 | (CDI Group) | obzpgmqurt = xsydoebvnh ynmvwlquww (zkmnxidann, svlaueswwl - xllmsqvjdf) View more | - | 24 Mar 2021 | ||
EI (EI Group (50 mg)) | obzpgmqurt = ounfrizwwy ynmvwlquww (zkmnxidann, vmyhrdknqe - fjwyaqafct) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free